GCG and fatty liver disease: Another study in DIO mice injected with a protease-resistant dual GLP-1/glucagon co-agonist showed similar results in terms of weight loss, lipid-lowering activity, anti-hyperglycemic efficacy, increased fatty acid oxidation and reduced hepatic steatosis [204].